TCGA-BH-A1FL-01A-11R-A13Q-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 56
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.250
- WNT_BETA_CATENIN_SIGNALING+0.190
- MITOTIC_SPINDLE+0.170
- DNA_REPAIR+0.150
- TGF_BETA_SIGNALING+0.100
- UV_RESPONSE_DN+0.070
- G2M_CHECKPOINT+0.060
- E2F_TARGETS+0.040
- MYC_TARGETS_V1+0.040
- PEROXISOME+0.040
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.540
- INTERFERON_GAMMA_RESPONSE-0.520
- ANGIOGENESIS-0.490
- INFLAMMATORY_RESPONSE-0.490
- ALLOGRAFT_REJECTION-0.480
- IL6_JAK_STAT3_SIGNALING-0.460
- CHOLESTEROL_HOMEOSTASIS-0.450
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.430
- MTORC1_SIGNALING-0.420
- COMPLEMENT-0.390
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR25617882 | — | B | 0.880 |
| 2 | MDT-AP-0038 | Med | Medulloblastoma | 0.876 |
| 3 | s_150324_3b | EPN | Posterior Fossa EPN | 0.865 |
| 4 | 88306 | EPN | Supratentorial EPN | 0.865 |
| 5 | 50d87a6b-8e96-4964-9f23-53cc48c7d9ff | — | — | 0.864 |
| 6 | SRR655864 | GTEX | — | 0.863 |
| 7 | BS_A87NPZAP | medulloblastoma | — | 0.860 |
| 8 | BS_HTEPAKCM | medulloblastoma | — | 0.860 |
| 9 | TCGA-LQ-A4E4-01A-11R-A266-07 | — | B | 0.860 |
| 10 | ERR2208948 | — | — | 0.859 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.250 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.190 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.170 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.150 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.100 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.070 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.060 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.040 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.040 | Inavolisib | — uncovered |
| PEROXISOME | 0.040 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.030 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.020 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.020 | Inavolisib | — uncovered |